Pivotal ECHO Study Provides Reassuring Evidence on HIV Risk and Contraceptives

Press Release: Pivotal ECHO Study Provides Reassuring Evidence on HIV Risk and Contraceptives

Durban and New York – Results of a pivotal clinical trial among 7,829 women ages 16-35 in East and Southern Africa provide important evidence to help inform women’s choices for contraception and HIV prevention. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study found no substantial difference in HIV risk among women using the three methods of contraception in the study – the copper-releasing intrauterine device (Cu-IUD), a levonorgestrel (LNG) implant (Jadelle) and depot medroxyprogesterone acetate-intramuscular (DMPA-IM), also known as Depo-Provera.

 

 

 

Published: 2019
Source: AVAC